Heterologous Prime-Boost Regimens Using rAd35 and rMVA Vectors Elicit Stronger Cellular Immune Responses to HIV Proteins Than Homologous Regimens

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Ratto Kim, Silvia ^a   Currier, Jeffrey R ^a   Cox, Josephine H ^b   Excler, Jean Louis ^b   Valencia Micolta, Anais ^a   Thelian, Doris ^a   Lo, Vicky ^a   Sayeed, Eddy ^b   Polonis, Victoria R ^a   Earl, Patricia L ^c   Moss, Bernard ^c   Robb, Merlin L ^a   Michael, Nelson L ^a   Kim, Jerome H ^a   Marovich, Mary A ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AD35 GE VACCINE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MVA C VACCINE; MVA KEA VACCINE; MVA TZC VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; GENE VECTOR; IMMUNIZATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PHENOTYPE; SPLEEN; SPLEEN CELL; T LYMPHOCYTE;

ADENOVIRIDAE; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV; HUMANS; IMMUNE SYSTEM; IMMUNITY, CELLULAR; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MICE; MICE, INBRED BALB C; SPLEEN; T-LYMPHOCYTES; VIRAL PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 84866858197     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045840     Document Type: Article

References (27)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
2. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, et al. (2008) HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372: 1894-1905.
3. Bot A, Qiu Z, Wong R, Obrocea M, Smith KA, (2010) Programmed cell death-1 (PD-1) at the heart of heterologous prime-boost vaccines and regulation of CD8+ T cell immunity. J Transl Med 8: 132.
4. Lu Y, Ouyang K, Fang J, Zhang H, Wu G, et al. (2009) Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope. Vaccine 27: 5411-5418.
5. McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, et al. (2003) Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9: 729-735.
6. Vuola JM, Keating S, Webster DP, Berthoud T, Dunachie S, et al. (2005) Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol 174: 449-455.
7. Wang S, Parker C, Taaffe J, Solorzano A, Garcia-Sastre A, et al. (2008) Heterologous HA DNA vaccine prime-inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine 26: 3626-3633.
8. Reyes-Sandoval A, Berthoud T, Alder N, Siani L, Gilbert SC, et al. (2010) Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 78: 145-153.
9. Honda M, Wang R, Kong WP, Kanekiyo M, Akahata W, et al. (2009) Different vaccine vectors delivering the same antigen elicit CD8+ T cell responses with distinct clonotype and epitope specificity. J Immunol 183: 2425-2434.
10. Sandstrom E, Nilsson C, Hejdeman B, Brave A, Bratt G, et al. (2008) Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 198: 1482-1490.
11. Xu J, Ren L, Huang X, Qiu C, Liu Y, et al. (2006) Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes. Aids 20: 2293-2303.
12. Lemckert AA, Sumida SM, Holterman L, Vogels R, Truitt DM, et al. (2005) Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol 79: 9694-9701.
13. Radosevic K, Rodriguez A, Lemckert AA, van der Meer M, Gillissen G, et al. (2010) The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clin Vaccine Immunol 17: 1687-1694.
14. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, et al. (2007) Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 81: 4654-4663.
15. Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, et al. (2010) Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One 5: e13983.
16. Bett AJ, Dubey SA, Mehrotra DV, Guan L, Long R, et al. (2010) Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans. Vaccine 28: 7881-7889.
17. Earl PL, Cotter C, Moss B, VanCott T, Currier J, et al. (2009) Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine 27: 5885-5895.
18. Tscharke DC, Woo WP, Sakala IG, Sidney J, Sette A, et al. (2006) Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB/c mice. J Virol 80: 6318-6323.
19. Roederer M, Nozzi JL, Nason MX, (2011) SPICE: Exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79 (2) (): 167-174.
20. Keefer M, Hachaambwa L, Bunce C, Cox J, Sayeed E, et al. (2010) Preliminary results of safety and immunogenicity of Ad35-GRIN/ENV HIV Vaccine in HIV-uninfected subjects. AIDS Res Hum Retroviruses 26: A-1-A-184.
21. Doe B, Walker CM, (1996) HIV-1 p24 Gag-specific cytotoxic T-lymphocyte responses in mice. Aids 10: 793-794.
22. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, et al. (2009) Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 15: 293-299.
23. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, et al. (2003) Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 4: 225-234.
24. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, et al. (2011) Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473: 523-527.
25. Reyes-Sandoval A, Wyllie DH, Bauza K, Milicic A, Forbes EK, et al. (2011) CD8+ T effector memory cells protect against liver-stage malaria. J Immunol 187: 1347-1357.
26. Pillai VK, Kannanganat S, Penaloza-Macmaster P, Chennareddi L, Robinson HL, et al. (2011) Different patterns of expansion, contraction and memory differentiation of HIV-1 Gag-specific CD8 T cells elicited by adenovirus type 5 and modified vaccinia Ankara vaccines. Vaccine 29: 5399-5406.
27. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, et al. (2012) Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482: 89-93.